# NAD IV Therapy: Infusions, Injectable Routes, Pharmacokinetics, and Quality Risk | NAD+ > NAD IV therapy: what the research shows about infusions and injectable NAD+, including rapid plasma clearance, weak controlled evidence, and the FDA Class I endotoxin recall. A documented digest. Infused NAD+ raises plasma NAD+ briefly, then clears within hours. The controlled evidence is the weakest of any route, and compounded injectables carry documented quality risk. Documented here as an unapproved compounded therapy, not an offer. ## The short version Here is NAD IV therapy in plain terms. An IV drip (or a shot) puts NAD+ (a fuel-handling helper molecule every cell uses) straight into your blood, skipping the gut. That sounds efficient, but two facts shape everything: the body clears infused NAD+ from the blood within a couple of hours, and these preparations are compounded — mixed by a pharmacy, not approved by the FDA, and at least one batch was recalled for contamination [10][11]. The strongest human evidence for raising NAD+ is actually for swallowed precursors (building blocks like NMN and NR), not for the drip. This page lays out why, with sources. ## Read this first **CAUTION — UNAPPROVED, COMPOUNDED ROUTE.** NAD IV therapy delivers NAD+ straight into the bloodstream in a wellness or clinical setting. It is a compounded preparation, not an FDA-approved drug, and the controlled evidence behind it is thin. Infused NAD+ does raise blood NAD+ — but only briefly, clearing from plasma within about two hours [10]. Compounded injectables have also carried a real quality risk: the FDA issued a Class I recall (its most serious tier) of a compounded NAD+ injection for elevated bacterial endotoxin [11]. This page documents what is known and what is missing about the injectable routes. It gives no dosing or timing instructions and sells nothing. ## How long NAD+ persists: infused clearance vs precursor elevation The pharmacokinetics (how the body absorbs and clears a substance) are the heart of the IV question. NAD+ itself is not freely taken up intact by most cells, and infused NAD+ is rapidly cleared: a pilot pharmacokinetic study using a continuous infusion found near-complete removal from plasma within roughly the first two hours [10]. Contrast that with oral precursors, which raise whole-blood NAD+ over days to weeks, with the elevation sustained through chronic 8–12 week dosing [4][3]. So an infusion produces a sharp, short spike; precursor capsules produce a slower, durable rise. This is the NAD+ half life picture in one line: infused NAD+ is gone from plasma in about two hours, while oral-precursor blood-NAD+ elevation persists for as long as dosing continues [10][4]. The practical implication is that the high plasma NAD+ an infusion produces is transient by design — the molecule does not linger the way a precursor-driven rise does. ## Injectable and IV NAD+: pharmacokinetics and quality risk Beyond IV infusion, NAD+ is also given by subcutaneous and intramuscular injection in compounded form, with minimal peer-reviewed pharmacokinetic data for those routes. Reported wellness-clinic infusion protocols run roughly 250–1000 mg per session over several hours; one formal pharmacokinetic study used a 3 µmol/min continuous infusion over six hours [10]. The slow infusion rate is itself telling — pushing NAD+ in faster is what tends to provoke the flushing, nausea, and chest or abdominal discomfort reported with the route, so protocols stretch the dose over hours to keep it tolerable [10]. The quality concern is concrete, not theoretical: NAD+ and its precursors are hygroscopic and degrade with heat and moisture, reconstituted injectable NAD+ must be kept cold and protected from light, and compounded injectables carry contamination and endotoxin risk — the basis for the FDA Class I recall already noted [11]. A Class I designation is the FDA's most serious recall tier, reserved for products with a reasonable probability of serious harm. None of these injectable routes is FDA-approved. ## Does NAD IV actually work? IV NAD+ has the weakest controlled evidence of any route. It reliably raises plasma NAD+ briefly, but that NAD+ is cleared within hours [10], and benefits for clinical outcomes are not established in rigorous trials — most available data are pilot or retrospective. By contrast, the controlled human data sit with oral precursors: NR and NMN raise blood NAD+ dose-dependently and improved metabolic and physical-performance endpoints in randomized trials [4][1][15]. Where you want controlled evidence, it is on the oral side, not the infusion side. ## What is an NAD injection? An NAD injection or IV infusion delivers NAD+ directly into the bloodstream in a wellness or clinical setting. It is a compounded, not FDA-approved, therapy with limited controlled evidence, and infused NAD+ is rapidly cleared from plasma within about two hours [10]. Subcutaneous and intramuscular injection forms exist but have minimal peer-reviewed pharmacokinetic data [11]. ## Is NAD+ shot worth it? Controlled evidence for injectable or IV NAD+ is weak; most data are pilot or retrospective, and infused NAD+ leaves plasma within about two hours [10]. Stronger controlled human data exist for oral precursors — NMN and NR — than for any shot or infusion [3][4]. This digest describes what studies measured and makes no recommendation. ## When should you inject NAD+? There is no established, evidence-based timing for injectable NAD+; protocols vary by wellness clinic and are not standardized in the peer-reviewed literature. This page documents what studies measured — chiefly rapid plasma clearance after infusion [10] — and gives no dosing or timing instructions. --- Documentation of the NAD+ record: the precursor trials logged green, the IV and injection gaps flagged amber, the species and route on every figure — no clinic behind the docs and nothing here dispensed, dosed, or sold.